Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria

Bibliography

• Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, editor. Brenner and Rector's the kidney. 8th edition. WB Saunders; Boston: USA: 2008. p. 1265-98
   Google Scholar
• Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 2007;8:952-9
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62
   PubMed Web of Science ®Google Scholar
• The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-92
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE Substudy. Lancet 2000;355:253-9
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, De Zeeuw D, et al. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes: a blood pressure independent effect. Circulation 2002;106:672-8
   PubMed Web of Science ®Google Scholar
• Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37:511-16
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ, Brinkman JW, Bakker SJ, et al. Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens 2006;15:631-6
   PubMed Web of Science ®Google Scholar
• Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin dependent diabetic patients. Am J Hypertens 1995;8:876-83
   PubMed Web of Science ®Google Scholar
• Schnack CH, Hoffman W, Hopmeier P, Schernthauer G. Renal and metabolic effects of 1-year treatment with ramipril or atenolol on NIDDM patients with microalbuminuria. Diabetologia 1996;39:1611-16
   PubMed Web of Science ®Google Scholar
• Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomized, double-blind, placebo-controlled trial (the DIABHYCAR study). BMJ 2004;328:495
   PubMed Web of Science ®Google Scholar
• Oda H, Kachi R, Ohashi H. Clinical usefulness of imidapril hydrochloride in diabetic nephropathy with hypertension. Progr Med 1995;15:2093-8
   Google Scholar
• Umeda M. Clinical effect of ACE-inhibitor imidapril on proteinuria excretion in hypertensive patients with type 2 diabetes. Jpn J Clin Exp Med 1999;76:1001-7
   Google Scholar
• Groppelli A, Omboni S, Ravogli A, et al. Validation of the SpaceLabs 90202 and 90207 devices for ambulatory blood pressure monitoring by comparison with intra-arterial resting and ambulatory measurements. J Hypertens Suppl 1991;9:S336
   Google Scholar
• Parati G, Bosi S, Castellano M. Guidelines for 24-h non-invasive ambulatory blood pressure monitoring:report from a working group of the Italian Society of Hypertension. High Blood Press 1995;4:168-74
   Google Scholar
• Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Condruit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Langenfeld MR, Friedrich A, et al. Angiotensin II related to sodium2 excretion modulates left ventricular structure in human essential hypertension. Circulation 1996;94(6):1304-9
   PubMed Web of Science ®Google Scholar
• Billings FT IV, Balaguer JM, C Y, et al. Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass. Clin Pharmacol Ther 2012;91(6):1065-73
   PubMed Web of Science ®Google Scholar
• Rawlins ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 2005;123(3):439-45
   PubMed Web of Science ®Google Scholar
• Mancia G, Omboni S, Ravogli A, et al. Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment: additional information from a large data base. Blood Press 1995;4:148-56
   PubMedGoogle Scholar
• Nelson MR, Stepanek J, Cevette M, et al. Noninvasive measurement of central vascular pressures with arterial tonometry: clinical revival of the pulse pressure waveform? Mayo Clin Proc 2010;85:460-72
   PubMed Web of Science ®Google Scholar
• Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004;17:118-23
   PubMed Web of Science ®Google Scholar
• Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-92
   PubMed Web of Science ®Google Scholar
• Skidgel RA. Bradykinin-degading enzymes: structure, function and potential roles in cardiovascular pharmacology. J Cardiovasc Pharmacol 1992;20(Suppl 9):S4-9
   PubMedGoogle Scholar
• Fox A, Lalloo U, Belvisi M, et al. Bradykinin-evoked sensitization of airway sensory nerves:a mechanism for ACE-inhibitor cough. Nat Med 1996;2:814-17
   PubMed Web of Science ®Google Scholar
• Sasaguri M, Ideishi M, Kinoshita A. Differential inhibition of bradykinin hydrolisis by four ACE inhibitors: a possible explanation for differences in induced coughing. Hypertens Res 1994;17:253-8
   Google Scholar
• Boonyapisit W, Tresukosol D. Comparison of the incidence of imidapril and enalapril induced cough. J Med Assoc Thai 2010;93(Suppl 1):S48-53
   PubMedGoogle Scholar
• Soleimani A, Nasiri O, Nikoueinejad H, et al. Prognostic value of B-type natriuretic peptide for assessment of left ventricular function in patients with chronic kidney disease. Iran J Kidney Dis 2011;5:242-7
   PubMed Web of Science ®Google Scholar
• Seki N, Nishimura M, Matsumoto T, et al. Relationship between BNP level and renal function in diabetic nephropathy with microalbuminuria. J Diabetes Complications 2013;27:92-7
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Kim S, Zhan Y, Iwao H. Role of intrarenal converting-enzyme in nephropathy of type II diabetic rats. Hypertens Res 2002;25:287-94
   PubMed Web of Science ®Google Scholar
• Hosova K, Ishimitsu T. Protection of cardiovascular system by imidapril,a versatile angiotensin-converting enzyme inhibitor. Cardiovasc Drug Rev 2002;20:93-110
   PubMedGoogle Scholar
• Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64-8
   PubMed Web of Science ®Google Scholar